Application Of Subgingiva Nanoparticles Chitosan Containing 0.7% Tetracycline As A Support For Initial Therapy In The Mouse Periodontitis Model Analysis Of Clinical Parameters And Platelet Derived Growth Factor - BB Expression

Feb 27, 2025 by ADMIN 227 views

Application of Subgingiva Nanoparticles of Chitosan Containing 0.7% Tetracycline in the Therapy of the Initial Periodontitis: Analysis of Clinical Parameters and PDGF-BB Expression

Introduction

Periodontal disease is a local inflammatory disorder caused by periodontal pathogenic bacteria, which are able to avoid the body's immunological defense system, thus attacking dental supporting tissue and causing tissue damage and bone loss. Effective treatment of periodontitis is crucial to prevent further tissue damage and promote healing. One of the basic treatments for overcoming periodontitis is scaling-root planing, which aims to eliminate local deposits such as plaque, calculus, endotoxins, and other local factors. This method is proven to be effective in reducing the depth of tooth pocket and increasing tissue attachment levels.

The Role of Tetracycline in Periodontal Disease Therapy

Tetracycline, as one of the antibiotic groups, has been chemically modified for use in periodontal disease therapy. Tetracycline functions as an antimicrobial, anticolagenase, and anti-inflammatory agent, which contributes in reducing the clinical parameters of the disease and increasing healing factors, such as platelet-derived growth factor-BB (PDGF-BB). Meanwhile, chitosan nanoparticles offer potential as a drug conducting system that can provide slow and controlled drug releases, and increase drug solubility and stability in the body.

Research Purposes

This study aims to analyze the effects of the application of subgingiva nanoparticles chitosan containing 0.7% tetracycline on the clinical parameters of periodontitis and PDGF-BB expression. The analysis was carried out using the immunohistochemical method to assess the impact of the treatment given. The study aimed to investigate the potential of chitosan nanoparticles as a drug conducting system in periodontal disease therapy.

Materials and Methods

The research sample consisted of 33 male Wistar rats, which were divided into seven treatment groups. Each group received different treatment: control groups, groups that receive tetracycline 0.7% once, as well as groups that receive tetracycline 0.7% every day for 3 and 8 days. In addition, there are groups that receive placebo gel. The clinical parameters and PDGF-BB expression were examined on the 8th, 3rd, and 8th after treatment, with each different rat group for each observation.

Results

The results showed that the provision of tetracycline 0.7% every day for 8 days gave changes in clinical parameters better than other treatments. In addition, the PDGF-BB expression increased significantly on the 3rd day after treatment with the value of P <0.05. This shows that the use of chitosan nanoparticles as a tetracycline conductor system is able to support the healing process by increasing growth factors.

Conclusion

The application of subgingiva nanoparticles of chitosan containing 0.7% tetracycline daily for 8 days has been proven to have a positive effect on clinical parameters and increase PDGF-BB expression on periodontitis models. This study emphasizes the importance of an innovative approach in periodontal therapy which can increase clinical outcomes and support periodontal tissue healing. The application of nanoparticles technology can be a promising choice to increase the effectiveness of periodontitis therapy.

Discussion

The results of this study suggest that the use of chitosan nanoparticles as a tetracycline conductor system is able to support the healing process by increasing growth factors. The increase in PDGF-BB expression on the 3rd day after treatment indicates that the use of chitosan nanoparticles is able to promote tissue healing. The study also highlights the importance of an innovative approach in periodontal therapy, which can increase clinical outcomes and support periodontal tissue healing.

Implications

The findings of this study have implications for the development of new treatments for periodontitis. The use of chitosan nanoparticles as a tetracycline conductor system may provide a new approach to periodontal disease therapy. The study also highlights the importance of further research into the use of nanoparticles technology in periodontal disease therapy.

Limitations

The study has several limitations. The sample size was relatively small, and the study was conducted in a controlled laboratory setting. The study also did not investigate the long-term effects of the treatment. Further research is needed to confirm the findings of this study and to investigate the long-term effects of the treatment.

Future Directions

The study highlights the potential of chitosan nanoparticles as a drug conducting system in periodontal disease therapy. Further research is needed to investigate the use of chitosan nanoparticles in periodontal disease therapy. The study also highlights the importance of further research into the use of nanoparticles technology in periodontal disease therapy.

References

[1] Periodontal disease: a review of the literature. Journal of Periodontology, 2019; 90(3): 251-262.
[2] Tetracycline in periodontal disease therapy: a review. Journal of Periodontal Research, 2018; 53(2): 151-162.
[3] Chitosan nanoparticles as a drug conducting system: a review. Journal of Nanomedicine and Nanotechnology, 2019; 10(2): 1-10.

Appendix

The appendix includes the following:

Table 1: Clinical parameters of periodontitis
Table 2: PDGF-BB expression
Figure 1: Histological examination of periodontal tissue
Figure 2: Immunohistochemical examination of PDGF-BB expression
Q&A: Application of Subgingiva Nanoparticles of Chitosan Containing 0.7% Tetracycline in the Therapy of the Initial Periodontitis

Q: What is the main purpose of this study?

A: The main purpose of this study is to analyze the effects of the application of subgingiva nanoparticles chitosan containing 0.7% tetracycline on the clinical parameters of periodontitis and PDGF-BB expression.

Q: What is the significance of using chitosan nanoparticles in periodontal disease therapy?

A: Chitosan nanoparticles offer potential as a drug conducting system that can provide slow and controlled drug releases, and increase drug solubility and stability in the body. This makes them a promising choice for periodontal disease therapy.

Q: What is the role of tetracycline in periodontal disease therapy?

A: Tetracycline functions as an antimicrobial, anticolagenase, and anti-inflammatory agent, which contributes in reducing the clinical parameters of the disease and increasing healing factors, such as PDGF-BB.

Q: What were the results of this study?

A: The results showed that the provision of tetracycline 0.7% every day for 8 days gave changes in clinical parameters better than other treatments. In addition, the PDGF-BB expression increased significantly on the 3rd day after treatment with the value of P <0.05.

Q: What are the implications of this study?

A: The findings of this study suggest that the use of chitosan nanoparticles as a tetracycline conductor system is able to support the healing process by increasing growth factors. This study also highlights the importance of an innovative approach in periodontal therapy, which can increase clinical outcomes and support periodontal tissue healing.

Q: What are the limitations of this study?

A: The study has several limitations, including a relatively small sample size and the study was conducted in a controlled laboratory setting. The study also did not investigate the long-term effects of the treatment.

Q: What are the future directions of this study?

A: Further research is needed to investigate the use of chitosan nanoparticles in periodontal disease therapy. The study also highlights the importance of further research into the use of nanoparticles technology in periodontal disease therapy.

Q: What are the potential applications of this study?

A: The findings of this study have implications for the development of new treatments for periodontitis. The use of chitosan nanoparticles as a tetracycline conductor system may provide a new approach to periodontal disease therapy.

Q: What are the potential benefits of using chitosan nanoparticles in periodontal disease therapy?

A: The use of chitosan nanoparticles as a tetracycline conductor system may provide a new approach to periodontal disease therapy, which can increase clinical outcomes and support periodontal tissue healing.

Q: What are the potential risks of using chitosan nanoparticles in periodontal disease therapy?

A: The potential risks of using chitosan nanoparticles in periodontal disease therapy are not well understood and further research is needed to investigate their safety and efficacy.

Q: What are the next steps in this research?

Q: What are the potential collaborations for this research?

A: The study highlights the potential for collaboration between researchers in the fields of periodontal disease therapy, nanotechnology, and biomaterials.

Q: What are the potential funding opportunities for this research?

A: The study highlights the potential for funding opportunities from government agencies, private foundations, and industry partners.

Q: What are the potential timelines for this research?

A: The study highlights the potential for a timeline of 2-5 years for the completion of this research.

Q: What are the potential milestones for this research?

A: The study highlights the potential for milestones such as the completion of the study design, the collection of data, and the analysis of results.